9th Annual Biomarkers Congress

View Profile


Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors
1. 2006 Targeted Therapy, in The Bethesda Handbook of Cancer Treatment, Eds, Abraham, J and Allegra C, Lippincott Williams and Williams, in press.
2. 2005 Terrorism and Cancer... Four Years After 9/11 Oncologist, 10; 663, 2005
3. 2004 The Means, the Mission, and the Pledge of The Oncologist, The Oncologist, 9: 1 - 2 , 2004
4. 2003 Johnston Cancer Fatigue: The Way Forward The Oncologist, 8: 27 – 30
5. 2003 A Masterpiece: The Life of Paul Calabresi (In Memoriam) The Oncologist, 8: 601, 2003.
6. 2003 Surveillance, Epidemiology and End Results Program: Report Card to the Nation The Oncologist, 10: 1634, 2003.
7. 2002 Clinical Trial Design for Target-Based Therapy. The Oncologist, 7: 401-409, 2002
8. 2001 CME Online: From the Oncologist, For the Oncologist The Oncologist, 6: 486,
9. 2001 Cancer and Terrorism The Oncologist 6: 401, 2001.
10. 2000 The Impact of Fatigue on Patients with Cancer: Overview of Fatigue 1 and 2. The Oncologist 5: 9-12
11. 2000 The Basic Immunology of ASCO. The Oncologist 5: 0
12. 2000 Use of Complementary Medicine by Adult Patients Participating in HIV/AIDS Clinical Trials. The Journal of Alternative and Complementary Medicine.Vol.6, 5:415-422
13. 2000 Curt, G A.: Breitbart, W., Cella, D., Groopman, J.E., Horning, S.J., Itri, L.M., Johnson, D.H., Miaskowski, C., Scherr, S.L., Portenoy, R.K. and Vogelzang, N.J The Oncologist 5:353-360
14. 2000 Use of Complementary Medicine by Adult Patients Participating in Cancer Clinical Trials. Oncology Nursing Forum Vol 27. No. 4 pp.623-630, 2000.
15. 1999 The Evolving Face of Palliative Care in Cancer Medicine. The Oncologist 4: 0, 1999.
16. 1998 Investment in Research as a National Priority The Oncologist, 3:1
17. 1998 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy: Dutch Treat Revisited. The Oncologist, 3: 267-268
18. 1997 Genistein-induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity Molecular Pharmacology 51 (2), 193-200
19. 1996 Cancer Nursing Comprehensive Textbook, 2nd Edition, Philadelphia, W.D. Saunders, pp. 470-484
20. 1996 Cancer Drug Development: New Targets for Cancer Treatment. The Oncologist, 1: 120, 1996
21. 1996 Issues in Antiemetic Therapy. Editorial, Cancer. Vol. 077:05, pp. 832-826, 1996.
22. 1993 Neoplasms associated with AIDS. In Medical Oncology Basic Principles and Clinical Management of Cancer McGraw Hill, Inc., New York. Second Edition, pp. 1173-1201
23. 1993 2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex A phase I trial. J. Infect. Disease pp. 21-29
24. 1993 Animal models in cancer drug discovery and development. In Cancer Medicine (Holland, J. and Frei, E., Eds.) Third Edition, pp. 653-666
25. 1993 Cancer; Principles and Practice of Oncology, 4th Edition J. B. Lippincott Co, pp. 2734-2747
26. 1992 Drug resistance as a biochemical target in cancer chemotherapy Vol. 13 Bristol-Myers Squibb Cancer Symposia Series (Tsuro, T. and Ogawa, M. eds) Academic Press in 1992.
27. 1990 unsound methods of cancer treatment. Curt, G.A, V.T., Hellman, S. and Rosenberg, S.A. (Eds.
28. 1990 Oral azidothymidine, continuous infusion 5-fluorouracil and oral leucovorin: A phase I study. J. Natl. Cancer Inst. 82:1710-1714
29. 1990 The clinical pharmacology of infusional chemotherapy. In Cancer Chemotherapy by Infusion, (Lokich, J., ed.) Pluribus Press, Inc
30. 1990 A phase I-II trial of continuous-infusion cisplatin, continuous infusion 5-fluorouracil, and VP-16 in colorectal carcinoma. AM. J. Clin., Oncol. pp. 455-458, 1990.
31. 1989 Treatment research in cancer. In Cancer Growth and Progression, (Kaiser, H.E., Series Editors); Fundamental Aspects of Cancer, Kluwer Academic Publishers, Dordrecht, pp. 162-
32. 1989 Methotrexzte resistance: mechanisms and implications. In Kessel, D. (Ed.), Drug Resistance, CRC Press, pp. 369-384
33. 1987 High-dose carboplatin in refractory ovarian cancer patients. J. Clin. Oncol. 5: 197-201
34. 1987 Effect of calcium channel blockers on human CRU-GM with cytotoxic drugs. J. Clin. Oncol. 5: 489-495
35. 1987 Cytosine arabinoside. In Lokich, J.J. (Ed.), Infusional Chemotherapy, Precept Press, Chicago pp. 161-166
36. 1987 Methotrexate. In Lokich, J.J. (Ed.), Infusional Chemotherapy Precept Press, Chicago pp. 123-129
37. 1987 Medical oncology: decade of discovery. Internal Medicine for the Specialist Vol. 8, No. 8: 74-84
38. 1987 Antimetabolites. In Pinedo, H.M., Longo, D.L. and Chabner, B.A. (Eds.), Cancer Chemotherapy and Biological Response Modifiers, Annual 9 Elsevier, Amsterdam pp. 1-22, 1987.
39. 1986 Cancer chemotherapy. In Ullman’s Encyclopedia Vol. A5, VCH Verlagsgesellschat, Weinheim, pp. 1-28
40. 1986 Drug resistance in colon cancer. In Mastromarino, A.J. (Ed.), Biology and Treatment of Colorectal Cancer Metastasis. Martinus Mijhoff Publishing, Boston, pp. 281-293. 1986.
41. 1986 Skin reactions induced by trimetrexate, and analog of methotrexate. Invest. New Drugs 4: 159-163, 1986.
42. 1986 Biochemistry of methotrexate. In Kimura, J. and Wang, Y.M. (Eds.), Methotrexate in Cancer Therapy Raven Press, New York, pp. 1-38, 1986.
43. 1986 Immunoaugmentative therapy: a primer on the perils of unproved treatments. J. Am. Med. Assoc. 255: 505-507
44. 1985 5-fluorouracil and methotrexate administered simultaneously as a continuous infusion. A phase I study. Cancer 56: 2395-2398, 1985
45. 1985 A phase I and pharmacology study of continuous-infusion low-dose methotrexate administration. Cancer 56: 2391-2394
46. 1985 Cancer Chemotherapy Annual 7 Cancer Chemotherapy Annual 7
47. 1985 The polyglutamation of methotrexate: Is methotrexate a prodrug? J. Clin. Invest. 76: 907-912, 1985.
48. 1985 Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow J. Clin. Invest. 75: 1008-1013, 1985.
49. 1985 Purification of myeloid progenitor cells (CFU-Cs) from normal human bone marrow using an immune-rosette technique Exper. Hematol. 13: 560-565, 1985
50. 1985 Determinants of the sensitivity of human small cell lung cancer cell lines to methotrexate. J. Clin. Invest. 76: 1323-1329, 1985
51. 1985 Competitive protein binding assay for trimetrexate. Cancer Treat. Rep. 69: 641-644, 1985
52. 1985 A phase I and pharmacokinetic study of dihydro-5-azacytidine (NSC-264880) Cancer Res. 45: 3359-3363
53. 1985 Drug resistance: A primary obstacle to progress in chemotherapy. J.B. Lippincott, Philadelphia, pp. 241-245, 1985.
54. 1984 Editorial: Surgical oncology research development: The perspective of the National Cancer Institute. Cancer Treat. Rep. 68: 825-829, 1984.
55. 1984 Antimetabolites. In Cancer Chemotherapy annual, Vol. 6, Pinedo, H.M. and Chabner, B.A. (Eds. Elsevier, Amsterdam, pp. 1-30, 1984..
56. 1984 Cancer chemotherapy: Progress and expectations, 1984. Cancer 54: 2599-2608
57. 1984 Synthesis and retention of methotrexate polyglutamates by human small cell lung cancer. Biochem. Pharmacol. 33: 1682-1685, 1984
58. 1984 Gene amplification in drug resistance: Of mice and men. J. Clin. Oncol. 2: 6264
59. 1984 Drug resistance in cancer. Cancer Treat. Rep. 68: 87-99, 1984.
60. 1984 Cytotoxic drugs active in leukemia. In The Leukemias, Goldman, J.M. and Preisler, H.D. (Eds.) Butterworth and Co., London, pp. 35-103, 1984..
61. 1983 Unstable methotrexate resistance in human small cell cancer associated with double minute chromosomes. N. Engl. J. Med. 308: 199-202, 1983.
62. 1983 Reversible acute pulmonary edema due to uncontrolled hyperglycemia in diabetic individuals with renal failure Diabetes Care 5: 506-511, 1983.
63. 1983 Introduction to symposium on drug resistance. Cancer Treat. Rep. 67: 855-857, 1983.
64. 1983 The pharmacology and clinical use of methotrexate. N. Engl. J. Med. 309: 1094-1104
65. 1983 A phase II and pharmacokinetic study of azididinylbenzoquone (AZQ) in high grade glioma. Cancer Res. 43: 6102-6105, 1983.
66. 1983 A phase I and pharmacokinetic study of CBDCA, carboplatin. Cancer Res. 43: 4470-4473, 1983.
67. 1983 Evidence for multiple drug resistance in human tumor cells lines. Cancer Treat. Rep. 67: 883-888, 1983.
68. 1983 Antimetabolites. In Cancer Chemotherapy Annual, Vol. 5, Pinedo, H.M. (Ed.), Excerpta Medica, Amsterdam, pp. 1-29,1983
69. 1982 Carboplatin for advanced colorectal carcinoma: a phase I study Cancer Treat. Rep. 70: 301-302, 1982.
70. 1982 Liposomally entrapped ara-CTP to overcome ara-C resistance in a murine lymphoma in vitro Brit. J. Cancer 45: 559-563, 1982.
71. 1982 In Cancer Chemotherapy Annual, Vol. 4, Pinedo, H.M. (Ed.), pp. 1-28, Elsevier, NewYork, 1982.
72. 1980 Acute renal failure induced by non-steroidal anti-inflammatory drugs. An. Intern. Med. 1: 72-73
73. 1979 Risk of acute renal failure following angiography in the elderly Angiology 30: 205-207, 1979.
74. 1977 Clinical pharmacology of a hepatoma-specific alkylating agent Biochem. Pharmacol. 26: 1715-1718, 1977.
75. 1976 Inhibition of nucleic acid synthesis by the butyl ester of methotrexate. Biochem. Pharmacol. 25: 1943-1946, 1976.
76. 1975 Cellular pharmacology of the di-n-butyl ester of methotrexate J. Clin. Pharmacol. 15: 556-557


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.